Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11555230 | 0.84 | MAP4K4 (0.40) | MAP4K4ALDH1A1PLAUIDO1 | |
| SCHEMBL1319218 | 0.84 | CYP3A4 (0.50) | MAP4K4KDM4EALDH1A1TSHRCASP1 | |
| SCHEMBL915037 | 0.82 | CYP3A4 (0.48) | MAP4K4KDM4EALDH1A1TSHRCASP1 | |
| SCHEMBL31382687 | 0.82 | SCN9A (0.39) | PIK3CBMAP4K4KDM4EIDO1 | |
| SCHEMBL4869343 | 0.82 | SCN9A (0.39) | PIK3CBMAP4K4KDM4EIDO1 | |
| Hydrochloric Acid SCHEMBL11549048 | 0.82 | CYP3A4 (0.48) | MAP4K4KDM4EALDH1A1TSHRCASP1 | |
| SCHEMBL4016084 | 0.82 | CASP1 (0.46) | MAP4K4NNMTKDM4EALDH1A1GLA | |
| SCHEMBL30370236 | 0.82 | CASP1 (0.46) | MAP4K4NNMTKDM4EALDH1A1GLA | |
| Lithium Ion SCHEMBL915036 | 0.81 | MAP4K4 (0.38) | MAP4K4KDM4EPLAUIDO1 | |
| SCHEMBL24405931 | 0.79 | SLC9A1 (0.39) | MAP4K4PLAUIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461825-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2019-04-03 | — | — | EP | disclosed |
| EP-2760865-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2018-07-11 | — | — | EP | disclosed |
| CN-103889986-B | Novel heterocyclic derivatives and their use | C&C新药研究所 | 2017-07-21 | — | — | CN | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
| US-9586959-B2 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES (KR) | 2017-03-07 | — | — | US | disclosed |
| EP-2271624-B9 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2760865-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2014-08-06 | — | — | EP | disclosed |
| CN-103889986-A | Novel heterocyclic derivatives and their use | C & C RES LAB | 2014-06-25 | — | — | CN | disclosed |
| EP-2271624-B1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| CN-102066327-A | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL | 2011-05-18 | — | — | CN | disclosed |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2271624-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131245-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | WO | disclosed |
| EP-2077262-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | ADRA1D, ADRB1, ADRB2 | PIK3CB 4124/4885MAP4K4 1859/4885NNMT 888/4885 |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | PIK3CB 4024/4885MAP4K4 1465/4885NNMT 848/4885 |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | PIK3CB 4024/4885MAP4K4 1465/4885NNMT 848/4885 |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | PIK3CB 4024/4885MAP4K4 1465/4885NNMT 848/4885 |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | PIK3CB 4024/4885MAP4K4 1465/4885NNMT 848/4885 |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | HRH4, HRH2, HRH1 | PIK3CB 2140/4885MAP4K4 475/4885NNMT 3828/4885 |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | ADRA1D, ADRB1, ADRB2 | PIK3CB 4024/4885MAP4K4 1465/4885NNMT 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.